021-51111890
购物车（0）
sales@molnova.cn
S49076 hydrochloride
CAS No. 1265966-31-1
S49076 hydrochloride ( S 49076 | S-49076 )
产品货号. M11116 CAS No. 1265966-31-1
S49076 盐酸盐是一种有效的 ATP 竞争性酪氨酸激酶抑制剂，抑制 MET、AXL/MER 和 FGFR1/2/3，IC50 小于 20 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥964 | 有现货 |
|
| 10MG | ￥1531 | 有现货 |
|
| 25MG | ￥2511 | 有现货 |
|
| 50MG | ￥3977 | 有现货 |
|
| 100MG | ￥7160 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称S49076 hydrochloride
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述S49076 盐酸盐是一种有效的 ATP 竞争性酪氨酸激酶抑制剂，抑制 MET、AXL/MER 和 FGFR1/2/3，IC50 小于 20 nM。
-
产品描述S49076 hydrochloride is a potent, ATP-competitive tyrosine kinase inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 of <20 nM, also potently inhibits the kinase activity of mutated isoforms of MET (D1246N, Y1248D, Y1248H) and FGFR1/2; only inhibits 6% of kinases on a panel of 442 human wild-type and mutated kinases at 100 nM; inhibits the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocks MET-driven migration of lung carcinoma cells, and inhibits colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL; causes tumor growth arrest in bevacizumab-resistant tumors in cancer xenograft models.Brain Cancer Phase 2 Clinical.
-
体外实验——
-
体内实验——
-
同义词S 49076 | S-49076
-
通路Tyrosine Kinase
-
靶点TAM Receptor
-
受体AXL|FGFR1|FGFR2|FGFR3|MER|Met
-
研究领域Cancer
-
适应症Brain Cancer
化学信息
-
CAS Number1265966-31-1
-
分子量474.96
-
分子式C22H23ClN4O4S
-
纯度>98% (HPLC)
-
溶解度DMSO: Soluble （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESC1COCCN1CC2=CNC(=C2)C=C3C4=C(C=CC(=C4)CN5C(=O)CSC5=O)NC3=O.Cl
-
化学全称3-[[2,3-dihydro-3-[[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene]-2-oxo-1H-indol-5-yl]methyl]-2,4-thiazolidinedione hydrochloride
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Burbridge MF, et al. Mol Cancer Ther. 2013 Sep;12(9):1749-62.
2. Clémenson C, et al. Mol Cancer Ther. 2017 Oct;16(10):2107-2119.
3. Rodon J, et al. Eur J Cancer. 2017 Aug;81:142-150.
